TABLE 3.
Baseline characteristics of patients assigned to receive irbesartan with (Intervention) or without (Nonintervention) the behavioural modification program AVAPROMISE
| Variable | Intervention (n=2402) | Nonintervention (n=2462) | Total (n=4864) |
|---|---|---|---|
| Age, years (range) | 57.6 (22–86) | 57.8 (16–89) | 57.7 |
| Age group, n (%) | |||
| Missing data | 59 (2) | 41 (2) | 100 (2) |
| 10–17 years | 2 (<1) | 0 | 2 (<1) |
| 18–29 years | 13 (1) | 16 (1) | 29 (1) |
| 30–39 years | 125 (5) | 113 (5) | 238 (5) |
| 40–49 years | 421 (18) | 443 (18) | 864 (18) |
| 50–59 years | 755 (31) | 751 (31) | 1506 (31) |
| 60–69 years | 625 (26) | 709 (29) | 1334 (27) |
| 70–79 years | 381 (16) | 375 (15) | 756 (16) |
| >80 years | 21 (1) | 14 (1) | 35 (1) |
| Sex, n (%) | |||
| Missing data | 101 (4) | 81 (3) | 182 (4) |
| Female | 1257 (52) | 1231 (50) | 2488 (51) |
| Hypertension duration, years | 5.8 | 5.4 | 5.6 |
| Systolic blood pressure, mmHg (SD) | 160 (16) | 160 (17) | 160 (16.7) |
| Diastolic blood pressure, mmHg (SD) | 95 (9) | 95 (9.6) | 95 (9.3) |
| Missing data, n (%) | 163 (7) | 118 (5) | 281 (6) |
| Newly diagnosed, n (%) | 218 (9) | 265 (11) | 483 (10) |
| Previously diagnosed, n (%) | 2021 (84) | 2079 (84) | 4100 (84) |
| 0–5 years | 1210 (50) | 1283 (52) | 2493 (51) |
| 6–10 years | 327 (14) | 358 (15) | 685 (14) |
| 11–15 years | 207 (9) | 186 (8) | 393 (8) |
| 16–20 years | 145 (6) | 119 (5) | 264 (5) |
| >20 years | 132 (6) | 133 (5) | 265 (5) |